Novartis AG’s small molecule phosphoinositide 3-kinase delta (PI3Kẟ) blocker CDZ173, which is in a registration-enabling study, is expected to reach the market in 2022 lastest. Activated Phosphoinositide 3-kinase Delta Syndrome (APDS) is an ultra-rare, debilitating primary immune deficiency which makes carriers of the underlying defect in the PIK3CD gene unable to fight of infections. Currently there is no approved treatment available for PIK3CD overactivity, which occurrs approximately 1-2 per million.
Follow Us
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.
Categories
Follow Us
Tags
AI
Alzheimer
antibodies
bacteria
binx health
Biosimilar
Blood Filter
Cancer
cardiovascular
cell therapy
CE Mark
clinical trial
colorectal cancer
Diagnostics
Digital Health
Drug Discovery
ExThera Medical
FDA
FDA approval
funding
fundraising
glycosylation
Halodoc
HIV
Innovation
Licensing
M&A
medical device
medtech
microbial
microbial DNA
microbial RNA
microbiome
Neuro
Novartis
pharma
Pharming
Prescient Metabiomics
robots
software
Therapeutics
Therapy
USA
VIrology
women health